On March 25, 2026, Japan’s largest pharmaceutical company, Takeda, unveiled a sweeping new restructuring initiative. The program aims to deliver more than 200 billion Japanese yen ($1.26 billion) in annual gross savings by the 2028 fiscal year to fund upcoming drug launches and late-stage pipeline development.
Strategic pillars of the transformation:
-
Operational Streamlining: Takeda plans to simplify corporate functions, “bringing leadership and teams closer to patients,” and leveraging advanced technologies to reduce procedural complexity.
-
Restructuring Investment: The company expects to incur 150 billion yen ($940 million) in restructuring expenses during the 2026 fiscal year. This follows a 2024 overhaul that saw a headcount reduction of over 1,800 employees (3.7% of its workforce).
-
Key Drivers: This move is a direct response to the rapid revenue decline of its ADHD blockbuster Vyvansefollowing its patent expiration.
-
Focus on High-Potential Assets: Reallocated resources will support three key upcoming treatments:
-
Oveporexton: For the treatment of narcolepsy.
-
Rusfertide: An injectable for the rare blood disorder polycythemia vera.
-
Zasocitinib: A TYK2 inhibitor aimed at rivaling Bristol Myers Squibb’s Sotyktu.
-
Leadership Perspective: Julie Kim, Takeda’s CEO-elect taking office in June, stated that these deliberate steps will strengthen the company’s ability to “execute with speed” while strategically prioritizing resources for long-term growth in the next era.
Source: https://www.fiercepharma.com/pharma/takeda-targets-13b-cost-savings-further-restructuring